On February 3, 2023, Atara Biotherapeutics, Inc. announced that Utpal Koppikar, the company's Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6998 USD | +0.94% | +9.34% | +36.47% |
May. 20 | Sector Update: Health Care Stocks Ease Monday Afternoon | MT |
May. 20 | Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.47% | 84.27M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.58% | 21.97B | |
-5.20% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- ATRA Stock
- News Atara Biotherapeutics, Inc.
- Atara Biotherapeutics, Inc. Announces the Resignation of Utpal Koppikar as Executive Vice President